BR112022024678A2 - Agonista de receptor ss de hormônio de tireoide inovador - Google Patents

Agonista de receptor ss de hormônio de tireoide inovador

Info

Publication number
BR112022024678A2
BR112022024678A2 BR112022024678A BR112022024678A BR112022024678A2 BR 112022024678 A2 BR112022024678 A2 BR 112022024678A2 BR 112022024678 A BR112022024678 A BR 112022024678A BR 112022024678 A BR112022024678 A BR 112022024678A BR 112022024678 A2 BR112022024678 A2 BR 112022024678A2
Authority
BR
Brazil
Prior art keywords
innovative
receptor agonist
thyroid hormone
disease
thyroid
Prior art date
Application number
BR112022024678A
Other languages
English (en)
Inventor
Yu Yongguo
Wang Yiqian
Ke Zunhong
Original Assignee
Chengdu kanghong pharmaceutical co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chengdu kanghong pharmaceutical co ltd filed Critical Chengdu kanghong pharmaceutical co ltd
Publication of BR112022024678A2 publication Critical patent/BR112022024678A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

AGONISTA DE RECEPTOR ß DE HORMÔNIO DE TIREOIDE INOVADOR. O presente pedido fornece agonistas de receptor ß do hormônio de tireoide inovadores com melhor atividade, seletividade ou segurança e que são representados pela Fórmula (I), e são usados para prevenir ou tratar doenças relacionadas a uma ação agonista do receptor ß. A doença inclui, por exemplo, obesidade, hiperlipidemia, hipercolesterolemia, diabetes, doença hepática (fígado gorduroso, NASH, NAFLD e similares), doenças cardiovasculares (aterosclerose e similares), doenças de tireoide (hipotireoidismo, câncer de tireoide, etc.).
BR112022024678A 2020-06-02 2021-06-02 Agonista de receptor ss de hormônio de tireoide inovador BR112022024678A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010491859 2020-06-02
CN202110178964 2021-02-09
PCT/CN2021/097986 WO2021244582A1 (zh) 2020-06-02 2021-06-02 新型甲状腺激素β受体激动剂

Publications (1)

Publication Number Publication Date
BR112022024678A2 true BR112022024678A2 (pt) 2022-12-27

Family

ID=78830664

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022024678A BR112022024678A2 (pt) 2020-06-02 2021-06-02 Agonista de receptor ss de hormônio de tireoide inovador

Country Status (9)

Country Link
US (1) US20230257367A1 (pt)
EP (1) EP4159723A1 (pt)
JP (1) JP2023528637A (pt)
KR (1) KR20230048481A (pt)
CN (1) CN115768751A (pt)
AU (1) AU2021283577A1 (pt)
BR (1) BR112022024678A2 (pt)
CA (1) CA3185710A1 (pt)
WO (1) WO2021244582A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102598832B1 (ko) * 2021-04-30 2023-11-07 재단법인 대구경북첨단의료산업진흥재단 피리미딘 유도체 또는 이의 염 및 이를 포함하는 약학적 조성물
WO2024059200A1 (en) 2022-09-14 2024-03-21 Halia Therapeutics, Inc. Nek7 inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100740383B1 (ko) 2000-02-17 2007-07-16 브리스톨-마이어스스퀴브컴파니 갑상선 수용체에 대한 아닐린 유도 리간드
EP1347959A1 (de) 2000-12-27 2003-10-01 Bayer Aktiengesellschaft Indol-derivate
RU2422450C2 (ru) 2003-11-19 2011-06-27 Метабазис Терапеутикс, Инк. Новые фосфорсодержащие тиромиметики
PT1919878E (pt) 2005-07-21 2010-11-02 Hoffmann La Roche Derivados de piridazinona como agonistas do receptor da hormona da tiróide
CA2758894C (en) 2009-04-20 2013-09-10 Mitsubishi Tanabe Pharma Corporation Novel thyroid hormone .beta. receptor agonist
JP2011088840A (ja) * 2009-10-21 2011-05-06 Daiichi Sankyo Co Ltd ５−ヒドロキシピリミジン−４−カルボキサミド化合物を含有する医薬組成物
JP5847533B2 (ja) * 2010-10-19 2016-01-27 田辺三菱製薬株式会社 新規甲状腺ホルモンβ受容体作動薬
US11485729B2 (en) * 2018-01-23 2022-11-01 Shenzhen Targetrx, Inc. Substituted pyridazinone compound
US20210292304A1 (en) * 2018-06-22 2021-09-23 Hinova Pharmaceuticals Inc. Deuterated mgl-3196 compound and use thereof
US20210355110A1 (en) * 2018-10-12 2021-11-18 InventisBio Co., Ltd. Thyroid hormone receptor agonists
US11203587B2 (en) * 2018-10-12 2021-12-21 Terns, Inc. Thyroid hormone receptor beta agonist compounds

Also Published As

Publication number Publication date
AU2021283577A1 (en) 2023-01-19
WO2021244582A1 (zh) 2021-12-09
CN115768751A (zh) 2023-03-07
JP2023528637A (ja) 2023-07-05
EP4159723A1 (en) 2023-04-05
CA3185710A1 (en) 2021-12-09
KR20230048481A (ko) 2023-04-11
US20230257367A1 (en) 2023-08-17

Similar Documents

Publication Publication Date Title
BR112022024678A2 (pt) Agonista de receptor ss de hormônio de tireoide inovador
PH12021551165A1 (en) Glp-1r agonists and uses thereof
EA202192684A1 (ru) Агонисты glp-1r и их применения
CL2012001722A1 (es) Compuestos derivados de 3-hidroxi-5-arilisotiazol, agonistas del receptor 40 acoplado a la proteina g (gpr40); composición farmacéutica que los comprende; y método para el tratamiento o la prevención de la diabetes.
PE20231639A1 (es) Compuestos co-agonistas del glucagon y peptido-1 similar al glugacon (glp-1)
CL2008000067A1 (es) Compuestos derivados de espirocromanona; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar el sindrome metabolico, higado graso, hiperlipemia, obesidad, diabetes, bulimia, neoplasma maligno o enfermedades infecciosas.
BR112017023849A2 (pt) anticorpos anti-ox40 e métodos de uso dos mesmos
SV2017005512A (es) Composiciones farmacéuticas para terapia combinada
BR112017008160A8 (pt) Peptídeo, composição, métodos para tratamento de um paciente ou indivíduo e para tratamento de uma doença metabólica, e, usos de um peptídeo e de uma composição
AR058122A1 (es) Combinacion de un antagonista / agonista inverso de h3 y un supresor del apetito
BR112022012594A2 (pt) Dosagem de gama-hidroxibutirato (ghb)
CL2008000667A1 (es) Compuestos derivados de fenoxi aminotiazolonas sustituidas, modulares de receptores alfa relacionados con estrogenos; composion farmaceutica que comprende a dichos compuestos; y sus uso para tratar cancer, sindrome metabolico, obesidad, diabetes.
CL2007001971A1 (es) Ester isopropilico del acido 4-[5-metoxi-6-(2-metil-6-[1,2,4]triazol-1-il-piridin-3-ilamino)-pirimidin-4-iloxi]-piperidin-1-carboxilico, agonista del receptor rup3, modulador del metabolismo de glucosa; composicion farmaceutica; y uso para tratar trastornos metabolicos, como diabetes, hiperlipidemia, hiperglicemia, obesidad
BR112021007902A2 (pt) Anticorpo anti-cd73, fragmento de ligação ao antigênio e aplicação dos mesmos
BR112022019789A2 (pt) Citocinas il-15 mascaradas, produtos de clivagem, ácido nucleico, vetor, célula hospedeira, composição, composição farmacêutica, kit e métodos de produção de uma citocina il-15 mascarada e de tratamento ou prevenção de câncer
BR112019002245A2 (pt) agonistas de receptor acoplado à proteína g
BRPI0809680A2 (pt) Compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por agonistas de lxr alfa e/ou lxr beta e uso dos compostos.
MX2023000887A (es) Metodo de reduccion de los efectos laterales asociados con la tiroides.
BR112022011032A2 (pt) Conjugado de anticorpo-fármaco anti-claudina e uso farmacêutico do mesmo
BR112022019532A2 (pt) Conjugados de neodegrader
BR112021024938A2 (pt) Anticorpos de receptor 1 de peptídeo natriurético e métodos de uso
BR112021011119A2 (pt) Composição farmacêutica
MX2022003251A (es) Anticuerpo contra gipr y su proteina de fusion con glp-1, y composicion farmaceutica y aplicacion de los mismos.
BR112022024058A2 (pt) Análogos de pth para o tratamento de hipoparatireoidismo
BRPI0519919A2 (pt) composições farmacêuticas compreendendo inibidores da nep, inibidores do sistema de produção de endotelina endógena e inibidores da hmg coa redutase